SOLARA.NS
Solara Active Pharma Sciences Limited [SOLARA.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SOLARA.NS Stock Summary
Top 10 Correlated Stocks
SOLARA.NS
In the News
SOLARA.NS Financial details
SOLARA.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 535.49 | 489.84 | 491.07 | 342.4 | 401.17 | |
| Net income per share | 24.11 | 44.29 | 69 | -16.18 | -6.16 | |
| Operating cash flow per share | 64.75 | 94.37 | 48.45 | -67.34 | 43.41 | |
| Free cash flow per share | 43.47 | -9.53 | -5.93 | -125.39 | 12.49 | |
| Cash per share | 2.51 | 27.53 | 70.53 | 15.8 | 6.15 | |
| Book value per share | 387.16 | 419.62 | 495.06 | 424.29 | 416.84 | |
| Tangible book value per share | 202.01 | 244.55 | 357.67 | 304.44 | 300.92 | |
| Share holders equity per share | 387.16 | 419.62 | 495.06 | 424.29 | 416.84 | |
| Interest debt per share | 247.55 | 305.14 | 218.45 | 307.36 | 306.45 | |
| Market cap | 11.08B | 11.5B | 44.7B | 23.94B | 11.79B | |
| Enterprise value | 15.7B | 18.16B | 48.93B | 33.85B | 21.83B | |
| P/E ratio | 18.61 | 10.04 | 20.19 | -41.17 | -53.16 | |
| Price to sales ratio | 0.84 | 0.91 | 2.84 | 1.95 | 0.82 | |
| POCF ratio | 6.93 | 4.71 | 28.76 | -9.89 | 7.54 | |
| PFCF ratio | 10.32 | -46.67 | -235.03 | -5.31 | 26.22 | |
| P/B Ratio | 1.16 | 1.06 | 2.81 | 1.57 | 0.79 | |
| PTB ratio | 1.16 | 1.06 | 2.81 | 1.57 | 0.79 | |
| EV to sales | 1.19 | 1.43 | 3.11 | 2.75 | 1.51 | |
| Enterprise value over EBITDA | 6.99 | 6.72 | 11.99 | 32.36 | 13.95 | |
| EV to operating cash flow | 9.82 | 7.44 | 31.48 | -13.99 | 13.97 | |
| EV to free cash flow | 14.63 | -73.69 | -257.27 | -7.51 | 48.57 | |
| Earnings yield | 0.05 | 0.1 | 0.05 | -0.02 | -0.02 | |
| Free cash flow yield | 0.1 | -0.02 | 0 | -0.19 | 0.04 | |
| Debt to equity | 0.56 | 0.66 | 0.39 | 0.68 | 0.68 | |
| Debt to assets | 0.27 | 0.34 | 0.24 | 0.35 | 0.35 | |
| Net debt to EBITDA | 2.06 | 2.46 | 1.04 | 9.47 | 6.42 | |
| Current ratio | 1 | 0.92 | 1.34 | 1.16 | 1.08 | |
| Interest coverage | 2.07 | 2.56 | 3.55 | -0.39 | 0.31 | |
| Income quality | 2.77 | 2.13 | 0.7 | 2.66 | -3.49 | |
| Dividend Yield | 0 | 0.01 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.11 | 0.09 | -0.19 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.02 | 0.02 | 0.03 | 0.16 | |
| Research and developement to revenue | 0 | 0.05 | 0.04 | 0.05 | 0.03 | |
| Intangibles to total assets | 0.24 | 0.21 | 0.17 | 0.15 | 0.14 | |
| Capex to operating cash flow | -0.33 | -1.1 | -1.12 | 0.86 | -0.71 | |
| Capex to revenue | -0.04 | -0.21 | -0.11 | -0.17 | -0.08 | |
| Capex to depreciation | -0.63 | -2.86 | -1.61 | -1.86 | -1 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 458.29 | 646.64 | 876.68 | 393.02 | 240.36 | |
| ROIC | 0.1 | 0.09 | 0.13 | -0.01 | 0.01 | |
| Return on tangible assets | 0.04 | 0.07 | 0.1 | -0.02 | -0.01 | |
| Graham Net | -248.97 | -243.84 | -69.59 | -185.61 | -185.67 | |
| Working capital | -9.42M | -579M | 2.69B | 1.68B | 864.2M | |
| Tangible asset value | 4.99B | 6.33B | 11.48B | 10.94B | 10.83B | |
| Net current asset value | -3.45B | -3.91B | 368.1M | -1.86B | -2.09B | |
| Invested capital | 0.56 | 0.66 | 0.39 | 0.68 | 0.68 | |
| Average receivables | 1.79B | 3.27B | 4.3B | 5.58B | 5.61B | |
| Average payables | 2.79B | 2.3B | 2.63B | 2.96B | 2.95B | |
| Average inventory | 2.04B | 2.5B | 2.87B | 4.35B | 5.67B | |
| Days sales outstanding | 98.91 | 84.89 | 130.87 | 163.63 | 144 | |
| Days payables outstanding | 119.45 | 123.12 | 146.7 | 148.32 | 141.53 | |
| Days of inventory on hand | 107.73 | 159.35 | 139.9 | 301.06 | 258.24 | |
| Receivables turnover | 3.69 | 4.3 | 2.79 | 2.23 | 2.53 | |
| Payables turnover | 3.06 | 2.96 | 2.49 | 2.46 | 2.58 | |
| Inventory turnover | 3.39 | 2.29 | 2.61 | 1.21 | 1.41 | |
| ROE | 0.06 | 0.11 | 0.14 | -0.04 | -0.01 | |
| Capex per share | -21.28 | -103.9 | -54.38 | -58.05 | -30.93 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 94.1 | 105.27 | 105.65 | 97.85 | 118.2 | |
| Net income per share | -2.77 | 0.12 | 1.05 | -5.43 | -4.77 | |
| Operating cash flow per share | 0 | 0 | 0.01 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0.01 | 0 | 0 | |
| Cash per share | 2.66 | 0 | 6.14 | 0 | 5.83 | |
| Book value per share | 416.72 | 0 | 416.41 | 0 | 406.79 | |
| Tangible book value per share | 298.63 | 0 | 300.61 | 0 | 292.45 | |
| Share holders equity per share | 416.72 | 0 | 416.41 | 0 | 406.79 | |
| Interest debt per share | 276.76 | 6.3 | 287.23 | 6.84 | 280.55 | |
| Market cap | 14.98B | 16.13B | 11.8B | 13.73B | 12.85B | |
| Enterprise value | 24.68B | 16.13B | 21.84B | 13.73B | 22.63B | |
| P/E ratio | -37.6 | 896.25 | 78.23 | -17.56 | -18.72 | |
| Price to sales ratio | 4.43 | 4.09 | 3.1 | 3.9 | 3.02 | |
| POCF ratio | 0 | 0 | 23.59K | 0 | 0 | |
| PFCF ratio | 0 | 0 | 23.59K | 0 | 0 | |
| P/B Ratio | 1 | 0 | 0.79 | 0 | 0.88 | |
| PTB ratio | 1 | 0 | 0.79 | 0 | 0.88 | |
| EV to sales | 7.29 | 4.09 | 5.74 | 3.9 | 5.32 | |
| Enterprise value over EBITDA | 78.88 | 30.92 | 40.86 | 64.9 | 58.32 | |
| EV to operating cash flow | 0 | 0 | 43.68K | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 43.68K | 0 | 0 | |
| Earnings yield | -0.01 | 0 | 0 | -0.01 | -0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.65 | 0 | 0.68 | 0 | 0.67 | |
| Debt to assets | 0.34 | 0 | 0.35 | 0 | 0.34 | |
| Net debt to EBITDA | 31 | 0 | 18.79 | 0 | 25.21 | |
| Current ratio | 1.06 | 0 | 1.08 | 0 | 1.03 | |
| Interest coverage | 0.12 | 1.02 | 1.23 | -0.28 | 0.52 | |
| Income quality | 0 | 0 | 0.01 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0.03 | 0 | |
| Intangibles to total assets | 0.15 | 0 | 0.14 | 0 | 0.14 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 161.16 | 0 | 99.02 | 0 | 208.95 | |
| ROIC | 0 | 0 | 0.01 | 0 | 0.01 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | -0.01 | |
| Graham Net | -200.56 | 0 | -185.48 | 0 | -191.55 | |
| Working capital | 625.6M | 32.4M | 864.2M | 88.9M | 295.7M | |
| Tangible asset value | 10.74B | 0 | 10.83B | 0 | 10.52B | |
| Net current asset value | -2.3B | 32.4M | -2.09B | 88.9M | -2.14B | |
| Invested capital | 0.65 | 0 | 0.68 | 0 | 0.67 | |
| Average receivables | 2.4B | 2.4B | 2.85B | 2.85B | 2.8B | |
| Average payables | 1.44B | 1.44B | 1.53B | 1.53B | 1.74B | |
| Average inventory | 2.74B | 2.74B | 2.79B | 2.79B | 2.78B | |
| Days sales outstanding | 127.88 | 0 | 134.69 | 0 | 118.69 | |
| Days payables outstanding | 136.9 | 0 | 143.05 | 0 | 131.86 | |
| Days of inventory on hand | 260.49 | 0 | 261.02 | 0 | 211 | |
| Receivables turnover | 0.7 | 0 | 0.67 | 0 | 0.76 | |
| Payables turnover | 0.66 | 0 | 0.63 | 0 | 0.68 | |
| Inventory turnover | 0.35 | 0 | 0.34 | 0 | 0.43 | |
| ROE | -0.01 | 0 | 0 | 0 | -0.01 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
SOLARA.NS Frequently Asked Questions
What is Solara Active Pharma Sciences Limited stock symbol ?
Solara Active Pharma Sciences Limited is a IN stock and trading under the symbol SOLARA.NS
What is Solara Active Pharma Sciences Limited stock quote today ?
Solara Active Pharma Sciences Limited stock price is $332.4 today.
Is Solara Active Pharma Sciences Limited stock public?
Yes, Solara Active Pharma Sciences Limited is a publicly traded company.
Company Profile
- Volume Average 134.03K
- Market Capitalization 11.97B
- Employee 2.36K
- CEO Mr. Poorvank Purohit
- Headquarters Chennai,IN
- IPO Date 2018-06-27
-
Website
https://www.solara.co.in 
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimalarial, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antitussive, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, central nervous system agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, lipid regulating agent, loop diuretic, muscarinic agonist, neuromuscular, OAB treatment, phenylalanine reducer, recovery of stroke, tardive dyskinesia, treatment of glaucoma and hyperphosphatemia, tropical anti-infective, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company exports its products. It operates in the Asia Pacific, Europe, North America, South America, and internationally. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.
